Navigation Links
Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
Date:3/13/2008

cies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand commercialization activities or consummate acquisitions; the accuracy of our estimations of the size of the market, and the potential market, for our products in specific disease areas; sales numbers and future guidance publicly provided by Boston Scientific Corporation regarding sales of their paclitaxel-eluting coronary stent products; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this report to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete preclinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the ability of Boston Scientific Corporation to successfully manufacture, market and sell their paclitaxel-eluting coronary stent products; the continued availability of capital to finance our activities; our ability to achieve the financial benefits expected as a result of the ac
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
2. Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
3. Angiotech announces results for the fourth quarter ended December 31, 2007
4. Angiotech to participate in Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
6. Angiotech and Symphony Medical Announce Licensing Agreement
7. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
8. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech to participate in Bank of America 2007 Credit Conference
11. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... the start of the military conflicts in Iraq and ... United States with traumatic brain injury caused by exposure ... improvised explosive devices, or IEDs. Symptoms of traumatic brain ... headaches and nausea, to more severe impairments in memory ... of Defense has recognized the critical importance and complexity ...
(Date:9/29/2014)... DUBLIN , Sept. 29, 2014 ... "Oligonucleotide Synthesis Market by Product & Services, End-User ... to their offering. The global oligonucleotide ... 2019 from $1,070.7 million in 2014, growing at a ... oligonucleotide synthesis market is categorized on the basis of ...
(Date:9/29/2014)... emerging diseases and biodiversity loss requires evolutionary thinking, ... Science Express that was co-authored by Bruce ... Agriculture and Life Sciences. , For the first ... reviewed progress in addressing a broad set of ... approaches that consider evolutionary histories and the likelihood ...
(Date:9/29/2014)... , Sept. 29, 2014 Research and ... Liquid Analyzer, Gas Analyzer, and Gas Chromatograph Market by ... Region - Global Trends & Forecast to 2013 - ... A process analyzer is a process analytical instrument that ... It has redefined the way by which companies carry ...
Breaking Biology Technology:Modeling shockwaves through the brain 2Modeling shockwaves through the brain 3Modeling shockwaves through the brain 4Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 2Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 3Evolutionary biology: It's not just for textbooks anymore 2Evolutionary biology: It's not just for textbooks anymore 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 2Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 4
... /Xinhua-PRNewswire-FirstCall/ --,China Biologic Products, Inc. (OTC Bulletin ... of the leading plasma-based pharmaceutical companies,in the ... that the Company,received approval from the PRC ... commence clinical trial of its new Human ...
... Cytotoxic ... Compound Market, ... development organization supporting the,pharmaceutical industry -- today announced the opening ... The 18,000 sq. ft. facility includes newly constructed analytical and,formulation ...
... (Nasdaq: SGMO ) announced today that Edward Lanphier,Sangamo,s ... progress of,Sangamo,s ZFP Therapeutic development programs and an overview ... Tuesday, September 23,2008, at the 2008 UBS Global Life ... will be webcast live and may be accessed via ...
Cached Biology Technology:China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII 2China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII 3Pharmatek Announces Official Opening of New Highly-Potent & Cytotoxic Development and Manufacturing Facility 2Sangamo BioSciences to Present at the UBS Global Life Sciences Conference 2
(Date:9/29/2014)... . Montreal, ... expectant mother was deprived of electricity during Quebec,s Ice ... a new study finds., Scientists from the Douglas Mental ... distinctive ,signature, in the DNA of children born in ... months after the event, researchers recruited women who had ...
(Date:9/29/2014)... Sclerosis (MS) were able to safely tolerate treatment with ... study published today in the journal Multiple Sclerosis ... first of its kind, was conducted by researchers at ... and collaborators at several other institutions. , While ... in the data also suggested that a preparation of ...
(Date:9/27/2014)... The first direct comparison of treating non-squamous lung ... to cisplatin has shown that the two combinations ... with more frequent adverse events. , At the ... from Chonnam National University Medical School, South Korea, ... trial that included 149 patients with non-squamous non-small ...
Breaking Biology News(10 mins):Cells from placentas safe for patients with multiple sclerosis 2Docetaxel or pemetrexed with cisplatin achieve comparable outcomes in non-squamous Lu Ca 2
... molecule made by the human body that triggers the immune ... to new research published today in Nature Medicine . ... that if scientists could block this signal, it may be ... is the most common autoimmune disease, affecting around 1 in ...
... canopies bear little resemblance to their seedlings, many described ... "Seedlings of Barro Colorado Island and the Neotropics," published ... Garwood, professor of plant biology at the University of ... describing seedling stages of tropical plants 25 years ago ...
... Lieberman (I-CT) and John Cornyn (R-TX) today introduced the ... ensure free, timely, online access to the published results ... proposed bill is welcomed by the Alliance for Taxpayer ... others formed to support open public access to publicly ...
Cached Biology News:New trigger for chronic inflammation in rheumatoid arthritis discovered 2New guide to tropical seedlings: Essential to climate change research 2Taxpayer Alliance applauds bill to broaden access to federal research results 2
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z71,381-3) ...
...
... Gel loading buffer is especially formulated for ... nucleic acids. The gel loading solution contains ... to add density and facilitate sample loading. ... that require divalent cations and SDS has ...
Biology Products: